Prelude Therapeutics Incorporated Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Prelude Therapeutics Incorporated (PRLD) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-127.17-121.83-115.44-111.69-56.93
Depreciation & Amortization1.771.175.630.920.54
Stock Based Compensation21.3525.6225.1420.935.58
Change in Working Capital4.22-10.482.643.634.62
Change in Accounts Payable3.31-2.27-0.353.901.16
Change in Other Working Capital1.591.941.281.333.46
Other Operating Activities1.591.9423.431.335.58
Net Cash from Operating Activities-102.89-107.06-83.73-83.53-46.18
Investing Activities
Capital Expenditures-0.76-3.513.02-2.320.62
Purchases of Investments-52.69-221.6384.71-261.480.00
Sales/Maturities of Investments143.65190.5084.71-261.480.00
Net Cash from Investing Activities90.19-34.6581.69-263.80-0.62
Financing Activities
Debt Repayment-0.400.000.000.00-0.26
Common Stock Issued0.33135.730.43161.42166.63
Common Stock Repurchased0.00-0.020.000.000.00
Other Financing Activities-0.16-0.020.00-0.30-0.01
Net Cash from Financing Activities-0.12136.400.82164.90246.23
Summary
Net Change in Cash-12.82-5.31-1.22-182.44199.43
Cash at Beginning of Period29.3434.6535.87218.3118.88
Cash at End of Period16.5229.3434.6535.87218.31
Free Cash Flow-103.65-110.58-86.75-85.85-46.80